Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($1.81), $0.83 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $33.22 million versus the consensus estimate of $59.28 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2026 revenue of $230-260 million, versus the consensus of $271.3 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.